No Data
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $42
Wedbush analyst Laura Chico maintains $Viridian Therapeutics(VRDN.US)$ with a buy rating, and maintains the target price at $42.According to TipRanks data, the analyst has a success rate of 47.9%
Optimistic Outlook for Viridian Therapeutics With Multiple Clinical Milestones Ahead
Express News | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now?
Ladenburg Thalmann Maintains Viridian Therapeutics(VRDN.US) With Hold Rating
Ladenburg Thalmann analyst Michael Higgins maintains $Viridian Therapeutics(VRDN.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 34.3% and a total average return
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $30 to $46
On Jun 12, major Wall Street analysts update their ratings for $Viridian Therapeutics(VRDN.US)$, with price targets ranging from $30 to $46.Needham analyst Serge Belanger maintains with a buy rating,